NCT02918266View on ClinicalTrials.gov

TAK-071 Scopolamine-Induced Cognitive Impairment Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

August 2, 2017

Study Completion Date

August 8, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Scopolamine

Scopolamine subcutaneous injection

DRUG

TAK-071

TAK-071 DIC

DRUG

Donepezil

Donepezil over-encapsulated tablet

DRUG

Scopolamine Placebo

Scopolamine placebo-matching subcutaneous injection

DRUG

TAK-071 Placebo

TAK-071 placebo-matching DIC

DRUG

Donepezil Placebo

Donepezil placebo-matching over-encapsulated tablet

Trial Locations (1)

Unknown

Glendale

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY